Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BIM-DRS Low Dose
BIM-DRS · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Bimatoprost-Drug Ring System Low Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System Low Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIM-DRS Low Dose | DRUG | Bimatoprost-Drug Ring System Low Dose |
| BIM-DRS High Dose | DRUG | Bimatoprost-Drug Ring System High Dose |
| SpyGlass IOL with silicone pads (no drug) | DEVICE | SpyGlass Intraocular Lens with silicone pads (no drug) |
Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Pseudophakic or planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
BIM-DRS Low Dose is an investigational small molecule being developed for glaucoma. It is designed for pseudophakic patients diagnosed with open angle glaucoma or ocular hypertension. The drug is delivered through a drug ring system and is currently in Phase 1 clinical development.
BIM-DRS Low Dose targets the PTGER2 receptor. This target is relevant to the treatment of glaucoma and ocular hypertension. The drug is being studied for its safety, efficacy, and dose response in patients with these conditions.
BIM-DRS Low Dose is being developed by SpyGlass Pharma, Inc., a company traded under the ticker SGP. The developer is conducting clinical research to evaluate the drug's potential in treating glaucoma and ocular hypertension.
BIM-DRS Low Dose is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess safety, efficacy, and dose response in patients with open angle glaucoma or ocular hypertension.
BIM-DRS Low Dose is being evaluated in one active Phase 1 clinical trial with the identifier NCT07641296. The trial is titled 'Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension' and has an enrollment target of 24 participants.